师资力量
热点新闻
2022-11-29
为深入学习贯彻习近平新时代中国特色社会主义思想和党的二十大精神,落...
最新公告
2022-11-29
公共管理学院2022年中南大学志愿服务先进集体、优秀志愿服务项目、优秀...

  黄鹏,男,医学博士,博士后,中南大学湘雅医院普通外科(甲状腺外科)医师,助理研究员。湖南省甲状腺疾病临床医学研究中心秘书,甲状腺及相关疾病诊疗技术湖南省工程研究中心秘书。主要从事甲状腺及相关疾病的临床及基础研究,熟悉甲状腺相关疾病临床诊治及超声引导下甲状腺细针穿刺技术。

 主持及参与在研的科研项目8项(按时间倒序排序):

  1. 国家自然科学基金青年项目,81902729eIF1AX通过启动CD147翻译促进女性甲状腺乳头状癌发生发展的机制研究,2020/01-2022/1220万,在研,主持;

  2. 中国博士后科学基金面上项目,2020M672517eIF1AX通过启动14-3-3γ翻译促进女性甲状腺乳头状癌发生的机制和应用研究,2020/01-2021/128万,在研,主持;

  3. 湖南省自然科学基金青年基金项目,2020JJ5904X连锁基因EIF1AX促进女性甲状腺乳头状癌发生发展的机制研究,2020/01-2022/125万,在研,主持;

  4. 中南大学湘雅医院青年基金项目,2018Q01X连锁基因EIF1AX促进女性甲状腺乳头状癌发生发展的机制研究,2019/01-2021/1210万,在研,主持;

  5. 国家自然科学基金面上项目,82070597,超保守lncRNA uc.67促进非酒精性脂肪肝病脂质沉积的机制及转化研究,2021/01-2024/1256万,在研,参与(排名第1);

  6. 国家自然科学基金面上项目,81974423CD147通过CCR7调控甲状腺乳头状癌淋巴结转移的机制研究,2020/01-2023/1255万元,在研,参与(排名第1);

  7. 湖南省重点领域研发计划,2019SK2031,甲状腺/乳腺结节智能诊断模型及个体化精准治疗体系的建立,2019/09-2021/08300万元,在研,参与(排名第1);

  8. 国家自然科学基金面上项目,81873640,维生素D受体增强5-ALA-PDTSHPT治疗效应的分子机制研究,2019/01-2022/1257万元,在研,参与(排名第1);

发表论文(按时间倒序排序_截止到20212月)

  1. Huang P, Tu B, Liao HJ, et al. Elevation of plasma tRNA fragments as a promising biomarker for liver fibrosis in nonalcoholic fatty liver disease. Scientific Reports, 2021. (第一作者)

  2. Liu M, Chen P, Hu HY, et al. Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer. Journal of cancer research and clinical oncology, 2021. (通讯作者)

  3. Tan HL, Khushbu RA, Yuan ZT, et al. A prediction model for contralateral central compartment lymph node metastases in unilateral papillary thyroid cancer. International Journal of Endocrinology, 2021. (通讯作者)

  4. Liu A, Yu H, Yang Y, et al. A Chemotherapy-Driven Increase in Mcl-1 Mediates the Effect of miR-375 on Cisplatin Resistance in Osteosarcoma Cells. OncoTargets and Therapy, 2020. (通讯作者)

  5. Li GY, Tan HL, Chen P, et al. Predictive Factors for Level V Lymph Node Metastases in Papillary Thyroid Carcinoma with BRAFV600E Mutation and Clinicopathological Features. Cancer Management and Research, 2020. (通讯作者)

  6. Yang Q, Chen P, Hu HY, et al. Preoperative sonographic and clinicopathological predictors for solitary lateral neck node metastasis in papillary thyroid carcinoma: a retrospective study. Cancer Management and Research, 2020. (通讯作者)

  7. Zhang Y, Huang P, Long M, et al. Intercalated kaolinite as an emerging platform for cancer therapy. Science China-Chemistry, 2019. (第一作者)

  8. Huang P, Huang FZ, et al. LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6. Metabolism, 2019. (第一作者)

  9. Huang P, Ouyang, DJ, et al. Chemotherapy-driven increases in the CDKN1A/PTN/PTPRZ1 axis promote chemoresistance by activating the NF-κB pathway in breast cancer cells. Cell Communication and Signaling, 2018. (第一作者)

  10. Huang P, Mao L F, Zhang Z P, et al. Down-Regulated miR-125a-5p Promotes the Reprogramming of Glucose Metabolism and Cell Malignancy by Increasing Levels of CD147 in Thyroid Cancer. Thyroid, 2018. (第一作者)

  11. Huang P, Kaluba B, Jiang XL, et al. Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis. BioMed Research International, 2018. (第一作者)

  12. Zhang Y, Long M, Huang P, et al. Intercalated 2D nanoclay for emerging drug delivery in cancer therapy. Nano Research, 2017. (第一作者)

  13. Zhang Y, Long M, Huang P, et al. Emerging integrated nanoclay-facilitated drug delivery system for papillary thyroid cancer therapy. Scientific Reports, 2016. (第一作者)

  14. Huang P, Chang S, Jiang X, et al. RNA interference targeting CD147 inhibits the proliferation, invasiveness, and metastatic activity of thyroid carcinoma cells by down-regulating glycolysis. International Journal of Clinical and Experimental Pathology, 2015. (第一作者)

  15. 苏获,毛林锋,Benson Kaluba, et al. 自制爬片装置用于细胞爬片及细胞染色.中国现代医学杂志, 2017. (通讯作者)

  16. 黄鹏, 常实, 江小林, et al. CD147 检测对细针穿刺细胞学可疑恶性的甲状腺结节的诊断价值. 中国普通外科杂志, 2014. (第一作者)

  17. 黄鹏, 常实. 超声引导经皮细针穿刺无水乙醇注射治疗甲状腺肿块研究进展. 医学综述, 2014. (第一作者)

 




上一篇:姜国俊
下一篇:何庆南